The William B. Abrams Lecture is a joint educational initiative of ASCPT and the FDA. The lecture series, supported in part by The Merck Company Foundation, was established in 1999 to honor William B. Abrams, MD, an ASCPT president from 1975 to 1976.
Among his many accomplishments, Dr. Abrams worked at the FDA as the first special government employee to establish the Center for Drug Evaluation and Research Staff College and develop its curriculum. He also had a distinguished career in the pharmaceutical industry as a longtime employee of Merck Research Laboratories.
For more than 10 years, ASCPT and the FDA have invited experts from academia, industry, and government to discuss advances in clinical pharmacology and drug development. These scientists have excelled in their specialty areas and are some of the most highly esteemed clinical pharmacologists in the field. Their presentations convey novel information and perspectives on fundamental aspects of clinical pharmacology. Previous lectures have included speakers from the Mayo Clinic, University of California, Children's Mercy Hospitals and Clinics, and the National Institutes of Health.
2020 ASCPT & FDA William B. Abrams Lecture
The 2020 ASCPT & FDA William Abrams Lecture Award recipient is Mary V. Relling, PharmD from St. Jude's Children's Research Hospital.
Clinical Implementation of Pharmacogenetics
: May 14, 2020
: 1:30 – 3 PM
: FDA White Oak, Building 2, Room 2047E
There are few select examples in pharmacogenetics for which the evidence from published research is already strong enough to support the use of genetic testing in the clinic. Pharmacogenetic testing in routine clinical care remains uncommon; one reason has been that the processes needed to move from genetic test results to specific prescribing recommendations have been unclear. This course will provide an overview of the Clinical Pharmacogenetics Implementation Consortium (CPIC®), developed in 2009, to write, curate, and update freely available, peer-reviewed, and detailed gene/drug pharmacogenetic clinical practice guidelines with accompanying computational tables to facilitate the appropriate use of pharmacogenetic tests in clinical care. In addition, the course will discuss implementation of the CPIC guidelines in a clinical protocol at St. Jude’s, PG4KDS, with an aim to preemptively test all eligible children at the institute and implement all CPIC guidelines by placing test results, with the necessary clinical decision support tools to guide prescribing, in an electronic health record. The rationale for preemptive testing is that the lifetime use of pharmacogenetically actionable drugs is high, almost all patients have at least one actionable genotype, and the cost of preemptively testing all pharmacogenetically actionable genes is low. For PG4KDS, over 5500 patients have been enrolled, and St. Jude has clinically implemented 12 genes and > 35 drugs: TPMT
for thiopurines; CYP2D6
for opiates, antidepressants, and ondansetron; CYP2C19
for voriconazole, clopidogrel, proton pump inhibitors and tricyclics; DPYD
for fluoropyrimidines; UGT1A1
for atazanavir; SLC01B1
for simvastatin; CYP3A5
for tacrolimus; CYP2C9
for celecoxib; mt-RNR1
and aminoglycosides; RYR1/CACNA1S
- Discuss the rationale for development and the purpose of the CPIC guidelines
- Demonstrate the practical utility of the CPIC guidelines in a clinical protocol
Check back for more information soon.
Adobe Connect or WebEx information will be provided at a later date.
If you have any questions about the ASCPT & FDA Abrams Award please contact Megan McBeath Hay